Altimmune (ALT) News Today $5.92 +0.72 (+13.85%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$6.02 +0.11 (+1.77%) As of 03/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Altimmune (NASDAQ:ALT) Receives "Market Perform" Rating from William BlairMarch 16 at 1:59 AM | americanbankingnews.comWilliam Blair Reaffirms "Market Perform" Rating for Altimmune (NASDAQ:ALT)William Blair reiterated a "market perform" rating on shares of Altimmune in a research report on Friday.March 15 at 10:09 PM | marketbeat.comAltimmune Sees Unusually High Options Volume (NASDAQ:ALT)Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the target of unusually large options trading activity on Friday. Investors purchased 25,356 call options on the company. This represents an increase of approximately 199% compared to the typical volume of 8,475 call options.March 15 at 3:14 PM | marketbeat.comAltimmune soars amid takeover speculationMarch 15 at 12:33 PM | msn.comAltimmune rises as buyout rumors follow R&D updatesMarch 15 at 12:33 PM | msn.comInsider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Purchases 10,000 Shares of StockAltimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory L. Weaver bought 10,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were bought at an average price of $5.20 per share, with a total value of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 15 at 10:27 AM | marketbeat.comInsider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Acquires 10,000 Shares of StockMarch 15 at 7:21 AM | insidertrades.comStifel Nicolaus Keeps Their Buy Rating on Altimmune (ALT)March 14 at 1:32 PM | markets.businessinsider.comEvercore bullish on Altimmune, likes drug move into alcohol related diseaseMarch 14 at 1:32 PM | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Altimmune (ALT)March 14 at 8:31 AM | markets.businessinsider.comAltimmune (ALT) Gets a Hold from William BlairMarch 14 at 8:31 AM | markets.businessinsider.comAltimmune to test obesity drug for alcohol use disorder and related health conditionsMarch 13 at 5:26 PM | reuters.comWhat is HC Wainwright's Estimate for Altimmune Q2 Earnings?Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Altimmune in a report issued on Monday, March 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.34) per share for the quarter,March 7, 2025 | marketbeat.comHC Wainwright Estimates Altimmune's Q2 Earnings (NASDAQ:ALT)March 7, 2025 | americanbankingnews.comHC Wainwright Has Negative View of Altimmune FY2029 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - Stock analysts at HC Wainwright decreased their FY2029 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $1.2March 6, 2025 | marketbeat.comAltimmune to Host Virtual R&D Day on March 13, 2025March 6, 2025 | globenewswire.comHC Wainwright Has Weak Outlook for Altimmune FY2029 EarningsMarch 6, 2025 | americanbankingnews.comAltimmune (ALT) Initiated with a Hold at William BlairMarch 5, 2025 | markets.businessinsider.comB. Riley Brokers Increase Earnings Estimates for AltimmuneAltimmune, Inc. (NASDAQ:ALT - Free Report) - Equities research analysts at B. Riley lifted their FY2025 EPS estimates for Altimmune in a report released on Friday, February 28th. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.86 per share for the year, up from their priMarch 4, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research report on Monday.March 3, 2025 | marketbeat.comAltimmune to Participate in the Leerink Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comB. Riley Has Optimistic Outlook of Altimmune FY2025 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - Stock analysts at B. Riley upped their FY2025 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Friday, February 28th. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.86 per shaMarch 3, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Altimmune (ALT) with Market Perform RecommendationMarch 1, 2025 | msn.comWilliam Blair Begins Coverage on Altimmune (NASDAQ:ALT)William Blair initiated coverage on shares of Altimmune in a research note on Friday. They set a "market perform" rating for the company.March 1, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.01 EPSAltimmune (NASDAQ:ALT - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%.February 28, 2025 | marketbeat.comAltimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2February 28, 2025 | seekingalpha.comAltimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In LineFebruary 28, 2025 | finance.yahoo.comAltimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comQ4 2024 Altimmune Inc Earnings CallFebruary 28, 2025 | finance.yahoo.comAltimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 PrintFebruary 28, 2025 | msn.comAltimmune Inc (ALT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D CostsFebruary 28, 2025 | finance.yahoo.comAltimmune initiated with a Market Perform at William BlairFebruary 27, 2025 | markets.businessinsider.comAltimmune files $400M mixed securities shelfFebruary 27, 2025 | markets.businessinsider.comAltimmune, Inc. (ALT) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comAltimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateFebruary 27, 2025 | globenewswire.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Buy" from AnalystsAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average recommendation of "Buy" by the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one hasFebruary 26, 2025 | marketbeat.comAltimmune appoints Teri Lawver, Jerry Durso to boardFebruary 26, 2025 | markets.businessinsider.comAltimmune Expands Board Amid Late-Stage Drug DevelopmentFebruary 25, 2025 | tipranks.comSeasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of DirectorsFebruary 25, 2025 | globenewswire.comAltimmune (ALT) to Release Earnings on ThursdayAltimmune (NASDAQ:ALT) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Up 8.7% - Time to Buy?Altimmune (NASDAQ:ALT) Trading 8.7% Higher - Here's WhyFebruary 20, 2025 | marketbeat.comAltimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025February 20, 2025 | globenewswire.comAltimmune put volume heavy and directionally bearishFebruary 20, 2025 | markets.businessinsider.comAltimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASHFebruary 18, 2025 | seekingalpha.comAltimmune, Inc. (NASDAQ:ALT) Short Interest Down 5.2% in JanuaryAltimmune, Inc. (NASDAQ:ALT - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 23,320,000 shares, a decrease of 5.2% from the January 15th total of 24,590,000 shares. Based on an average daily trading volume, of 3,190,000 shares, the short-interest ratio is presently 7.3 days.February 18, 2025 | marketbeat.comH.C. Wainwright maintains Buy on Altimmune stock, $12 targetFebruary 6, 2025 | msn.comHC Wainwright Reiterates "Buy" Rating for Altimmune (NASDAQ:ALT)HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Altimmune in a research note on Wednesday.February 5, 2025 | marketbeat.comWith 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big gunsFebruary 4, 2025 | uk.finance.yahoo.comAltimmune, Inc. (NASDAQ:ALT) Receives $20.83 Average Target Price from AnalystsAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has been assigned a consensus rating of "Buy" from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strFebruary 4, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Buy" by AnalystsAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and oneFebruary 1, 2025 | marketbeat.com Remove Ads Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.620.77▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼168▲ALT Articles Average Week Remove Ads Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Travere Therapeutics News Disc Medicine News IDEAYA Biosciences News Kiniksa Pharmaceuticals News Immunocore News Schrödinger News Wave Life Sciences News Amphastar Pharmaceuticals News Dyne Therapeutics News Indivior News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALT Stock Alerts